Revolution Medicines, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for RAS-addicted cancers. The company's core business model revolves around its research and development pipeline, specifically focusing on the RAS signaling pathway, which is implicated in approximately 30% of all human cancers. Its proprietary pipeline features a suite of RAS(ON) inhibitors, including its lead candidate daraxonrasib (RMC-6236), a multi-selective inhibitor, as well as mutant-selective inhibitors like elironrasib (RMC-6291) and zoldonrasib (RMC-9805). These small-molecule drugs are designed to suppress diverse oncogenic variants of RAS proteins by targeting their active, GTP-bound state.
As a pre-revenue, clinical-stage biotechnology firm, Revolution Medicines does not yet generate commercial product sales. Instead, its revenue model relies on capital markets, strategic partnerships, and royalty financing to fund its extensive clinical trials and research operations. Operating primarily out of the United States, the company aims to commercialize its therapies for use by oncologists in hospital and clinic settings once regulatory approvals are secured. Its competitive position is defined by its specialized focus on frontier oncology targets that have historically been considered "undruggable," positioning it as an innovator in the precision medicine landscape.
